Video
Dr. Surena Matin discusses significance of OLYMPUS trial, Jelmyto
Author(s):
“[Low-grade upper tract urothelial carcinoma] is fairly uncommon, yet it’s common enough that every urologist comes across it,” says Surena F. Matin, MD.
Video Player is loading.
In this video, Surena F. Matin, MD, discusses the significance of the OLYMPUS trial of mitomycin-containing reverse thermal hydrogel (Jelmyto) for low-grade upper tract urothelial carcinoma and how the treatment addresses an unmet therapeutic need. Final results of the OLYMPUS trial were presented at the 2020 Society of Urologic Oncology annual meeting. Matin is a professor urology at the University of Texas MD Anderson Cancer Center, Houston.
Related Videos
Gopa Iyer, MD, highlights findings from FORAGER-1 in metastatic urothelial carcinoma
Michael Schweizer, MD, shares data on mevrometostat plus enzalutamide in mCRPC
Laura Bukavina, MD, highlights study of urinary microbiome profiling
Kate Gessner, MD, on the mechanisms of immunotherapy failure in RCC
Darren Feldman, MD, on clinical outcomes in R/R testicular germ cell tumors
ASCO GU recap: Insights on 5 key trials
Laurence Albiges, MD, on COSMIC-313 trial of triplet vs doublet combination in aRCC
Francesca Jackson-Spence, MRCP, on efficacy of savolitinib/durvalumab in papillary renal cancer
Gopa Iyer, MD, on durable efficacy of EV/pembrolizumab in urothelial carcinoma
David Braun, MD, on phase 2 trial of an individualized neoantigen therapy for RCC
Related Content
